NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Warrants issued and outstanding (Details)	6 Months Ended
	Mar. 31, 2021 $ / shares shares
Warrants [Roll Forward]
Warrants, Outstanding at the beginning of the period	820,939
Warrants, Outstanding at the end of the period	820,939
Warrants, Exercisable at the end of the period	820,939
Weighted average exercise price, Outstanding at the beginning of the period \| $ / shares	$ 19.44
Weighted average exercise price, Outstanding at the end of the period \| $ / shares	19.44
Weighted average exercise price, Exercisable at the end of the period \| $ / shares	$ 19.44
Weighted average remaining contractual term, Outstanding at the end of the period	1 year 2 months 12 days
Weighted average remaining contractual term, Exercisable at the end of the period	1 year 2 months 12 days
December 13, 2021
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	20,627
Warrants, Exercisable at the end of the period	55.00
April 10, 2022
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	695,312
Warrants, Exercisable at the end of the period	20.00
July 6, 2023
Warrants [Roll Forward]
Warrants, Outstanding at the end of the period	105,000
Warrants, Exercisable at the end of the period	8.73